The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Paolo - France has a 2 gene target policy on their pcr tests. Always has had - however 2 gene target has more problems for testing covid. For a start it doubles the reagents needed, increases the testing time, and actually increases the chances of an inaccurate test. This is why NCYT's PCR test is the best out there as it overcomes these obstacles. Germany wouldn't be one of our biggest markets if it wasn't the best as they already have a great testing platform in place but still want NCYT. If you actually want to learn more before you spout rubbish please do your research. I'd suggest reading this where primerdesign actually state why 1 gene is better.
https://blog.primerdesign.co.uk/1-vs-2-gene-covid-19-assay-find-out-from-our-experts-which-is-best-for-testing-during-the-covid-19-pandemic/
And just to add even if our old friend Sea Doc was an actually practising GP, what the hell do they know about dna diagnostics. I'll tell you, nothing, nada. He has just googled that no GP ever delves into the science behind it, they are completely different paradigms. Doctors accept the science they are given by guess what scientists. No question, just pass on what they were told. If they were told to stick leaches on your bum they would do it. Unfortunately most of them whilst great and doing the world a great service are not free thinkers and certainly not great investors.
We've been over this so many times. FIND who do the WORLD HEALTH ORGANISATION diagnostic logistics have done tests on both Sensitivity and Specificity on many products. There results can be found here.
https://www.finddx.org/covid-19/sarscov2-eval-molecular/molecular-eval-results/
There findings are that PrimerDesign is 100% specific and 100% sensitive. Go figure. Don't listen to ramblings of some lovely old Doc who sails the oceans - go to the source. It really is that simple. Remember he is shorting this, so is going to point counter points to the contrary. Think, think hard now, is he really a doc, does he really sail, or do you just trust someone who say's he is on a bb and just as gullably believe it, when all the info is out there with access to google. Come on folks, sharpen up.
Swervy - bejesus just read the financial reports from a couple of weeks ago - profit margins are at over 50%. I despair sometimes at this board. The amount of hogwash that goes on that could be simply rectified by actually reading the RNS's. Sorry that's not all directed at you Swervy, but at the general idiocy shown on this bb of late. Unbelievable.
https://twitter.com/PrimerdesignLtd/status/1265244142201864192
"Our primary focus is to expand Primerdesign's manufacturing capacity as quickly as possible to service the continued significant demand for our Covid19 test"
Continued Significant Demand. I don't think you need to worry about them selling their products.
That was in February - now read this from April from the UN. They are building and building Africa's PCR testing capabilities up and up.
https://www.un.org/africarenewal/news/coronavirus/south-africa’s-covid-19-testing-capacity-increased-60-new-mobile-lab-units-launched
That is what the WHO have been doing since February building increasing Labs and PCR testing kits across Africa. See this article
https://reliefweb.int/report/world/more-20-african-countries-can-now-test-coronavirus-disease
Parkez, the PCR kit is a common kit in every laboratory in the world. Most African countries have them, however in smaller numbers than Western countries. However as part of the WHO programme is to supply vulnerable countries with more PCR testing machines. The WHO already scaled this up back in February in anticipation of covid testing needs in Africa. By then they'd set up 42 labs across Africa to utilise PCR testing. That is why NCYT being WHO approved is so important, and will greatly benefit the likes of Africa - until you're WHO approved you won't be going to these countries.
Good post GLR - In answer to your first question - yes that is exactly what the WHO approval does for those countries that lack the necessary means to test diagnostic kits themselves, and allows UN to deliver these kits to those in need. This was why the UK gov got the 4m order out to Egypt
"The UK is the G7 lead on support to vulnerable countries, and has confirmed a responsive funding package of more than GBP700m, including a GBP130m contribution to the UN, GBP65m of which is allocated to the World Health Organisation (WHO)"
Yep we are pretty much approved in most of the highest populated countries in the world. I think the last few weeks sp action and lack of news has made many investors question their NCYT investment. Just remember NCYT are selling to 100+ countries. Some orders will be small, but many I'd imagine will be in the region of the initial order we know about in Egypt (4m tests). Then understand why they are ramping up production, and bringing in Exsig which will allow faster and cheaper production - this will potentially massively increase capacity. These tests will be faster and allow POC mobile tests also. Just let that sink in before you get down beat.
Sonic - last month was a bumper month due to the deal with UK department of health for 6 months. We can't expect those sort of deals every month, hence quickdraws caution. However we do know there was a 4m test order agreed with Egypt in this period which alone could count for approx. £28m+ in rev so in all likelihood there is a very good chance we'll exceed the 36m that quickdraw forecast.
Smokie - no one with any integrity cares if you're a lady or man. However posting continuously on something one claims to not be invested in but having a vested interest in is duplicitous would one not agree. It is not because you are a lady, but it is your posts by its very nature are deceitful, as you just want to buy in lower. You still see worth in the company, but will deride it so you can get your buy in price. Basically its not demonstrating the finer qualities of being social morally sound. That is why I'd I imagine you get the flak that you basically rightfully receive.
Chart is still looking promising, setting up a nice bull flag, potential looks like a breakout or if we're unfortunate breakdown occurs next week. If it does breakout some very interesting targets on the fib around 670 and 900.
That's what NCYT's new product Exsig is all about, its approx. 4x faster than our current test, mainly due to prep time due to a massive reduction in reagents needed. Its also cheaper to produce. Also an Exsig POC portable test is coming soon . I'm looking forward to updates on these, and they can't come soon enough for me.